CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Public ClinicalTrials.gov record NCT01227577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP). The study is designed to evaluate early and deep molecular responses up to 4 years on nilotinib treatment. The primary end point is Rate of confirmed CMR in newly diagnosed Philadelphia chromosome positive CML-CP patients."
Study identification
- NCT ID
- NCT01227577
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 128 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2010 (Type not available)
- Primary completion
- Nov 2014 (Actual)
- Completion
- Nov 2014 (Actual)
- Last update posted
- Feb 8, 2016
2010 – 2014
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center, Inc. | Anaheim | California | 92801 | — |
| Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer | Burbank | California | 91505-6866 | — |
| Bay Area Cancer Research Dept.ofBayAreaCancerResearch | Concord | California | 94520 | — |
| St. Jude Heritage Medical Group Virginia Crosson Cancer Center | Yorba Linda | California | 92886 | — |
| Sarah Cannon Research Institute SCRI | Jacksonville | Florida | 32256 | — |
| Advanced Medical Specialties | Miami | Florida | 33176 | — |
| Pasco Hernando Oncology | New Port Richey | Florida | 34652 | — |
| Georgia Regents University MedCollege of GA Cancer Ctr 2 | Augusta | Georgia | 30912 | — |
| Stroger Cook County Hospital Division of Hematology & Onc | Chicago | Illinois | 60612 | — |
| Louis A. Weiss Memorial Hospital | Chicago | Illinois | 60640 | — |
| Indiana Blood and Marrow Institute | Beach Grove | Indiana | 46107 | — |
| Cancer Center of Kansas | Witchita | Kansas | 67214-3728 | — |
| LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3) | New Orleans | Louisiana | 70115 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| St. Louis University Cancer Center | St Louis | Missouri | 63110 | — |
| University of Nebraska Medical Center University of Nebraska Med Ctr | Omaha | Nebraska | 68198 | — |
| Hackensack University Medical Center Dept.of HackensackUniv.MedCtr. | Hackensack | New Jersey | 07601 | — |
| University of Rochester Medical Ct James P Wilmot Cancer Ctr | Rochester | New York | 14642 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Duke University Medical Center Duke University Med Ctr | Durham | North Carolina | 27710 | — |
| Oregon Health & Science University | Portland | Oregon | 97201 | — |
| Cancer Centers of the Carolinas Cancer Center | Greenville | South Carolina | 29605 | — |
| Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology | Chattanooga | Tennessee | 37404 | — |
| The Jones Clinic | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Baylor Research Institute Baylor Research Institute (17) | Dallas | Texas | 75204 | — |
| Oncology Consultants Oncology Consultants, P.A. | Houston | Texas | 77024 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01227577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2016 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01227577 live on ClinicalTrials.gov.